CL2012003091A1 - Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas. - Google Patents

Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas.

Info

Publication number
CL2012003091A1
CL2012003091A1 CL2012003091A CL2012003091A CL2012003091A1 CL 2012003091 A1 CL2012003091 A1 CL 2012003091A1 CL 2012003091 A CL2012003091 A CL 2012003091A CL 2012003091 A CL2012003091 A CL 2012003091A CL 2012003091 A1 CL2012003091 A1 CL 2012003091A1
Authority
CL
Chile
Prior art keywords
lupus erythematosus
treatment
apollolosus
thymid
subacute
Prior art date
Application number
CL2012003091A
Other languages
English (en)
Spanish (es)
Inventor
Gergely Peter
Wallstrom Erik
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42199281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2012003091A1 publication Critical patent/CL2012003091A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/30Sulfides having the sulfur atom of at least one thio group bound to two carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2012003091A 2010-05-06 2012-11-06 Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas. CL2012003091A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10162079 2010-05-06

Publications (1)

Publication Number Publication Date
CL2012003091A1 true CL2012003091A1 (es) 2013-03-22

Family

ID=42199281

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003091A CL2012003091A1 (es) 2010-05-06 2012-11-06 Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas.

Country Status (24)

Country Link
US (1) US20130172297A1 (https=)
EP (1) EP2566470A1 (https=)
JP (1) JP2013530937A (https=)
KR (1) KR20130066630A (https=)
CN (1) CN102869353A (https=)
AU (1) AU2011249784B2 (https=)
BR (1) BR112012028190A2 (https=)
CA (1) CA2795394A1 (https=)
CL (1) CL2012003091A1 (https=)
CR (1) CR20120566A (https=)
CU (1) CU20120154A7 (https=)
EA (1) EA201201514A1 (https=)
EC (1) ECSP12012312A (https=)
IL (1) IL222690A0 (https=)
MA (1) MA34285B1 (https=)
MX (1) MX2012012926A (https=)
NZ (1) NZ603999A (https=)
PE (1) PE20130612A1 (https=)
PH (1) PH12012502418A1 (https=)
SG (1) SG185746A1 (https=)
TN (1) TN2012000509A1 (https=)
TW (1) TW201201814A (https=)
WO (1) WO2011138393A1 (https=)
ZA (1) ZA201207710B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519539B (zh) * 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
US9289494B2 (en) * 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
DE60235900D1 (de) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
JP4571497B2 (ja) * 2002-09-19 2010-10-27 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
BRPI0407658A (pt) * 2003-02-18 2006-02-21 Kyorin Seiyaku Kk derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
EP1628957B1 (en) * 2003-05-26 2010-09-29 Takeda Pharmaceutical Company Limited Sulfopyrroles
ATE449069T1 (de) 2003-08-28 2009-12-15 Novartis Pharma Gmbh Aminopropanolderivate
CA2553704C (en) * 2004-02-11 2011-04-19 Basilea Pharmaceutica Ag Substituted benzimidazoles and their use for inducing apoptosis
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
ES2529724T3 (es) * 2005-09-09 2015-02-25 Novartis Ag Tratamiento de enfermedades autoinmunes

Also Published As

Publication number Publication date
WO2011138393A1 (en) 2011-11-10
EP2566470A1 (en) 2013-03-13
ECSP12012312A (es) 2012-12-28
CA2795394A1 (en) 2011-11-10
CU20120154A7 (es) 2013-03-27
TW201201814A (en) 2012-01-16
NZ603999A (en) 2014-06-27
CR20120566A (es) 2013-01-09
JP2013530937A (ja) 2013-08-01
IL222690A0 (en) 2012-12-31
ZA201207710B (en) 2013-06-26
MA34285B1 (fr) 2013-06-01
PE20130612A1 (es) 2013-06-06
EA201201514A1 (ru) 2013-05-30
MX2012012926A (es) 2012-12-17
KR20130066630A (ko) 2013-06-20
AU2011249784A1 (en) 2012-12-20
PH12012502418A1 (en) 2018-03-21
SG185746A1 (en) 2013-01-30
US20130172297A1 (en) 2013-07-04
AU2011249784B2 (en) 2014-03-06
TN2012000509A1 (en) 2014-04-01
CN102869353A (zh) 2013-01-09
BR112012028190A2 (pt) 2016-08-02

Similar Documents

Publication Publication Date Title
UY34851A (es) Inhibidores macrocíclicos de virus flaviviridae
LT3661514T (lt) Mavakamtenas, skirtas naudoti gydant hipertrofinę kardiomiopatiją
CL2016002310A1 (es) Nuevos compuestos bicíclicos.
PL3035936T3 (pl) Pewne jednostki chemiczne, kompozycje i sposoby
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MX384420B (es) Cultivo, producción, procesamiento y uso de cannabis de especialidad.
CR20140576A (es) Sintesis de compuestos heterociclicos
GT201200289A (es) 3-sustituido-5-fluoro-4-imino-3,4-dihidropirimidina-2-(1h)-onas como fungicidas
PL3495473T3 (pl) Sposób rozszczepienia hydrolitycznego zearalenonu i/lub pochodnych zearalenonu przy pomocy polipeptydu, jak i jego zastosowanie
EP3673877C0 (en) SYSTEMS FOR THE TREATMENT OF POLYCYSTIC OVARIAN SYNDROME
PL2613774T3 (pl) Kombinacja fenoksybenzaminy i polimyksyny E do leczenia zakażeń drobnoustrojowych
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
MX381488B (es) Indoles para su uso en la infección por el virus de la gripe.
IT1400509B1 (it) Apparecchiatura e metodo per il trattamento di disidratazione spinta di fanghi.
LT3113858T (lt) Konjugatų il-15/il-15r alfa pagrindu gryninimo būdas
EA201490559A1 (ru) Композиция для лечения свища
EA201792096A2 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
DK3019452T3 (da) Fremgangsmåde for og installation af biologisk denitrifikation af spildevand
MX386150B (es) Tasimelteon para tratar el síndrome de smith-magenis.
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
UA107346C2 (en) Use of nifuratel to treat infections caused by atopobium species
PL3393984T3 (pl) Instalacja i sposób biologicznego przetwarzania odpadów i ścieków organicznych
ES2663096T3 (es) Métodos para el tratamiento del síndrome nefrótico y de afecciones relacionadas
CL2012003091A1 (es) Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas.